WO2017165317A3 - Thérapies, vaccins et procédés prédictifs pour flavivirus - Google Patents

Thérapies, vaccins et procédés prédictifs pour flavivirus Download PDF

Info

Publication number
WO2017165317A3
WO2017165317A3 PCT/US2017/023260 US2017023260W WO2017165317A3 WO 2017165317 A3 WO2017165317 A3 WO 2017165317A3 US 2017023260 W US2017023260 W US 2017023260W WO 2017165317 A3 WO2017165317 A3 WO 2017165317A3
Authority
WO
WIPO (PCT)
Prior art keywords
flaviviruses
vaccines
therapies
virus
predictive methods
Prior art date
Application number
PCT/US2017/023260
Other languages
English (en)
Other versions
WO2017165317A2 (fr
Inventor
Samuel Bogoch
Elenore S. Bogoch
Anne-Elenor BOGOCH BORSANYI
Samuel Winston Bogoch
Original Assignee
Samuel Bogoch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Bogoch filed Critical Samuel Bogoch
Publication of WO2017165317A2 publication Critical patent/WO2017165317A2/fr
Publication of WO2017165317A3 publication Critical patent/WO2017165317A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des thérapies, des vaccins et des procédés prédictifs pour des flavivirus, comprenant le virus Zika, le virus de la dengue et le virus de l'encéphalite japonaise, et permet d'obtenir des composés pour le diagnostic, la prévention et le traitement d'épidémies du virus Zika, du virus de la dengue et du virus de l'encéphalite japonaise.
PCT/US2017/023260 2016-03-20 2017-03-20 Thérapies, vaccins et procédés prédictifs pour flavivirus WO2017165317A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662310800P 2016-03-20 2016-03-20
US62/310,800 2016-03-20

Publications (2)

Publication Number Publication Date
WO2017165317A2 WO2017165317A2 (fr) 2017-09-28
WO2017165317A3 true WO2017165317A3 (fr) 2017-11-02

Family

ID=59899728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/023260 WO2017165317A2 (fr) 2016-03-20 2017-03-20 Thérapies, vaccins et procédés prédictifs pour flavivirus

Country Status (1)

Country Link
WO (1) WO2017165317A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (fr) 2015-07-21 2023-08-02 ModernaTX, Inc. Vaccins contre les maladies infectieuses
WO2017070624A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre des maladies tropicales
EP3582790A4 (fr) 2017-02-16 2020-11-25 ModernaTX, Inc. Compositions immunogènes très puissantes
WO2019055807A1 (fr) 2017-09-14 2019-03-21 Modernatx, Inc. Vaccins à arn contre le virus zika

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
US20070249032A1 (en) * 2004-07-12 2007-10-25 Tengen Biomedical Company Flavivirus vaccine
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
WO2015077522A1 (fr) * 2013-11-22 2015-05-28 Samuel Bogoch Thérapies, vaccins et procédés de prévision pour le syndrome d'effondrement des essaims d'abeilles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
US20070249032A1 (en) * 2004-07-12 2007-10-25 Tengen Biomedical Company Flavivirus vaccine
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
WO2015077522A1 (fr) * 2013-11-22 2015-05-28 Samuel Bogoch Thérapies, vaccins et procédés de prévision pour le syndrome d'effondrement des essaims d'abeilles

Also Published As

Publication number Publication date
WO2017165317A2 (fr) 2017-09-28

Similar Documents

Publication Publication Date Title
WO2017165317A3 (fr) Thérapies, vaccins et procédés prédictifs pour flavivirus
WO2017172645A3 (fr) Méthodes de modification génétique de bactériophages
BR112017017511A2 (pt) sistemas e métodos para melhorar a variabilidade da frequência cardíaca
WO2018006074A3 (fr) Composés et méthodes permettant de moduler la fonction de l'arn
TW201614067A (en) Virus like particle comprising modified envelope protein E3
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
WO2017136450A3 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
MX2021004464A (es) Compuestos de tiazolida para el tratamiento de infecciones virales.
WO2016007540A3 (fr) Compositions et méthodes pour le traitement d'une infection par le virus de la dengue
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
WO2017087912A3 (fr) Biocapteurs ratiométriques et transfert d'énergie par résonance de förster non modulé géométriquement
ZA201707951B (en) Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
WO2016167944A3 (fr) Compositions et méthodes permettant de traiter l'hyperperméabilité intestinale
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
WO2015095735A3 (fr) Compositions de vaccin et leurs utilisations
WO2014160987A3 (fr) Vaccins comprenant des polypeptides de leishmania pour le traitement et le diagnostic de la leishmaniose
EA202090548A1 (ru) Вакцина для применения в профилактике и/или лечении заболевания
WO2017066796A3 (fr) Modulateurs de maladies impliquant des télomères
WO2016172417A3 (fr) Interactions entre membres des familles ceacam et tim
WO2016193945A3 (fr) Méthodes et compositions permettant de diagnostiquer, traiter et surveiller le traitement de troubles associés à une déficience en shank3
HK1246215A1 (zh) 去細胞角膜及其製備方法和用途
WO2016109002A3 (fr) Méthodes et compositions pour le traitement de troubles liés à l'irradiation
EP3461486C0 (fr) Composition pharmaceutique pour la prévention ou le traitement de la démence et l'amélioration de la fonction cognitive, comprenant de l'acanthoside b issue d'un extrait de salicorne
WO2014160985A3 (fr) Vaccins comprenant des polypeptides de leishmania pour le traitement et le diagnostic de la leishmaniose
EP3548457A4 (fr) Procédé amélioré pour la préparation de 2,3,3,3-tétrafluoropropène

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17770927

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17770927

Country of ref document: EP

Kind code of ref document: A2